Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Who May Qualify: - Age: ≥18 years of age - diagnosed by tissue sample (biopsy-confirmed) diagnosis of HER-2 positive solid tumor as defined in the protocol - Part 1: presence of advanced or metastatic disease that has progressed during or following previous treatment - Part 2: Early stage HER-2 positive cancers with high risk for relapse following completion of SOC or after neoadjuvant systemic treatment - AAV specified capsid total antibody ≤1:400 - You should be able to carry out daily activities with 0 level of ability (ECOG 0) or 1 - Life expectancy ≥3 months - Protocol-specified ranges for renal, liver, cardiac and pulmonary function - Protocol-specified ranges for hematology parameters Who Should NOT Join This Trial: - Hepatoxicity (AST or ALT \> 2x upper limit of normal) - Known active CNS or leptomeningeal disease - History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy - Pregnant or nursing (lactating) women - History of other malignancy within 5 years prior to screening as defined in protocol - History of hypersensitivity to corticosteroids or history of corticosteroid-related toxicity Concurrent anti-cancer treatment in another investigational trial Always talk to your doctor about whether this trial is right for you.